Dr. David H. Lam, MD
Cardiology (Cardiovascular Disease Physician)
550 17th Ave Ste 680
Seattle, WA 98122
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 3,046
Licensed in Washington since 2016, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
WA license MD60641815 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Swedish Medical Center Seattle, WA
- Swedish Medical Center / Cherry Hill Seattle, WA
- Swedish Edmonds Hospital Edmonds, WA
- Olympic Medical Center Port Angeles, WA
- Swedish Issaquah Issaquah, WA
Medical groups
- Swedish Health Services (79 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 3,046
- Services billed
- 5,939
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,791 | 1,525 |
| Established patient office or other outpatient visit, 30-39 minutes | 429 | 278 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 408 | 403 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 110 | 109 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 107 | 107 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 96 | 93 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 85 | 82 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 83 | 78 |
| Ultrasound of heart, follow-up | 82 | 79 |
| New patient office or other outpatient visit, 45-59 minutes | 79 | 79 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $736 in total to this clinician.
| Stryker Corporation | $588 |
|---|---|
| Atricure, Inc. | $148 |
| Travel and Lodging | $588 |
|---|---|
| Food and Beverage | $148 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Stryker Corporation May 21, 2025 | Travel and Lodging SCOPIS ENT · INSTRUMENTS · travel to FORT LAUDERDALE, FL | $588 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $51,502 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Evaluate the Efficacy in Reducing Atrial Fibrillation Burden (AFB) as Well as the Safety, Tolerability, and Pharmacokinetics of Oral PKN…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.